Orion Oyj - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Orion Oyj - Product Pipeline Review - 2016', provides an overview of the Orion Oyj's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Orion Oyj, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Orion Oyj - The report provides overview of Orion Oyj including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Orion Oyj's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Orion Oyj's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Orion Oyj's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Orion Oyj - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Orion Oyj's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Orion Oyj Snapshot 6 Orion Oyj Overview 6 Key Information 6 Key Facts 6 Orion Oyj - Research and Development Overview 7 Key Therapeutic Areas 7 Orion Oyj - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Orion Oyj - Pipeline Products Glance 15 Orion Oyj - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Orion Oyj - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Orion Oyj - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Orion Oyj - Drug Profiles 21 (budesonide + formoterol fumarate) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 (fluticasone propionate + salmeterol xinafoate) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 levosimendan 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ODM-201 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 dexmedetomidine hydrochloride 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ODM-109 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ODM-204 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ODM-104 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ODM-108 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ODM-203 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Drugs to Agonize GABA-B Receptor for Central Nervous System Disorders 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ORM-10103 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ORM-3819 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit BET Bromodomain for Oncology 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for Pain 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Orion Oyj - Pipeline Analysis 40 Orion Oyj - Pipeline Products by Target 40 Orion Oyj - Pipeline Products by Route of Administration 42 Orion Oyj - Pipeline Products by Molecule Type 43 Orion Oyj - Pipeline Products by Mechanism of Action 44 Orion Oyj - Recent Pipeline Updates 45 Orion Oyj - Dormant Projects 51 Orion Oyj - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 deramciclane 52 nitecapone 52 ODM-102 52 ODM-106 52 ORM-10921 52 Orion Oyj - Company Statement 53 Orion Oyj - Locations And Subsidiaries 55 Head Office 55 Other Locations & Subsidiaries 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Orion Oyj, Key Information 6 Orion Oyj, Key Facts 6 Orion Oyj - Pipeline by Indication, 2016 8 Orion Oyj - Pipeline by Stage of Development, 2016 10 Orion Oyj - Monotherapy Products in Pipeline, 2016 11 Orion Oyj - Combination Treatment Modalities in Pipeline, 2016 12 Orion Oyj - Out-Licensed Products in Pipeline, 2016 13 Orion Oyj - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 Orion Oyj - Pre-Registration, 2016 15 Orion Oyj - Phase III, 2016 16 Orion Oyj - Phase II, 2016 17 Orion Oyj - Phase I, 2016 18 Orion Oyj - Preclinical, 2016 19 Orion Oyj - Discovery, 2016 20 Orion Oyj - Pipeline by Target, 2016 40 Orion Oyj - Pipeline by Route of Administration, 2016 42 Orion Oyj - Pipeline by Molecule Type, 2016 43 Orion Oyj - Pipeline Products by Mechanism of Action, 2016 44 Orion Oyj - Recent Pipeline Updates, 2016 45 Orion Oyj - Dormant Developmental Projects,2016 51 Orion Oyj - Discontinued Pipeline Products, 2016 52 Orion Oyj, Subsidiaries 55
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.